 |
PDBsum entry 1ozc
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Signaling protein
|
PDB id
|
|
|
|
1ozc
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nat Struct Biol
10:629-636
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation.
|
|
F.M.Décaillot,
K.Befort,
D.Filliol,
S.Yue,
P.Walker,
B.L.Kieffer.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The high resolution structure of rhodopsin has greatly enhanced current
understanding of G protein-coupled receptor (GPCR) structure in the off-state,
but the activation process remains to be clarified. We investigated molecular
mechanisms of delta-opioid receptor activation without a preconceived structural
hypothesis. Using random mutagenesis of the entire receptor, we identified 30
activating point mutations. Three-dimensional modeling revealed an activation
path originating from the third extracellular loop and propagating through
tightly packed helices III, VI and VII down to a VI-VII cytoplasmic switch. N-
and C-terminal determinants also influence receptor activity. Findings for this
therapeutically important receptor may apply to other GPCRs that respond to
diffusible ligands.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Locations of activating mutations. (a) Mutated
amino acids are highlighted on a schematic representation of the
human -opioid
receptor sequence using single-letter amino acid codes. N- and
C-terminal mutated amino acids as well as Phe159, Pro182 and
Thr213 are shown in black circles. Mutated amino acids of groups
1, 2, 3 and 4 are highlighted in orange, green, yellow and blue,
respectively. Mutated residues that are part of well-known GPCR
structural motifs are Trp173, Pro182, Trp274, Tyr318 and Arg258
and mutated residues that are moderately to well conserved are
Lys214, Met262, Val283, Leu286, Tyr308 and Glu323. To orient our
mutated residues relative to well described, common class-A GPCR
amino acid residues, a white square indicates one of the most
conserved residues in each helix: Asn67 (hI), Asp95 (hII),
Arg146 (hIII), Trp173 (hIV), Pro225 (hV), Pro276 (hVI) and
Pro315 (hVII). (b) Except for the residues indicated in black,
the mutated residues were modeled and spatially clustered into
four groups. Position of modeled residues is indicated on a
three-dimensional model (PDB accession code 1OZC) with side
chains shown in yellow.
|
 |
Figure 5.
Figure 5. Mechanism for -opioid
receptor activation by an agonist. Schematic of receptor
showing a series of activation events proposed from our analysis
of CAM delta receptors. Postulated helical movements are
indicated by arrows. Step A: the opioid agonist (black bar)
binds to e3 and possibly to N-terminal determinants. This
perturbs the e3 hydrophobic cluster, thereby destabilizing
hVI-hVII interactions of the helical bundle near the
extracellular side of the receptor. Step B: the amphiphilic
agonist enters the binding pocket, disrupting both hydrophobic
(hIII-hVI) and hydrophilic (hIII-hVII) interactions and
provoking outward hIII-hVI-hVII movements. hIII moves toward the
hII-hIV interface while hVI and hVII separate from each other.
Step C: helical movements propagate downward within the
receptor, break cytoplasmic ionic locks (hVI-hVII from our study
and perhaps hIII-hVI; see text) and possibly release putative
hVIII. This reveals receptor intracellular determinants that
interact better with G proteins^52. Mutations from group 1 mimic
step A, mutations from groups 2 and 3 simulate events in step B,
and group 4 mutations produce structural modifications as in
step C.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nat Struct Biol
(2003,
10,
629-636)
copyright 2003.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
R.T.Kendall,
and
S.E.Senogles
(2011).
Isoform-specific uncoupling of the D(2) dopamine receptors subtypes.
|
| |
Neuropharmacology,
60,
336-342.
|
 |
|
|
|
|
 |
B.L.Kieffer,
and
C.J.Evans
(2009).
Opioid receptors: from binding sites to visible molecules in vivo.
|
| |
Neuropharmacology,
56,
205-212.
|
 |
|
|
|
|
 |
Q.Zhao
(2009).
Protein thermodynamic structure.
|
| |
IUBMB Life,
61,
600-606.
|
 |
|
|
|
|
 |
T.E.Angel,
M.R.Chance,
and
K.Palczewski
(2009).
Conserved waters mediate structural and functional activation of family A (rhodopsin-like) G protein-coupled receptors.
|
| |
Proc Natl Acad Sci U S A,
106,
8555-8560.
|
 |
|
|
|
|
 |
V.Micovic,
M.D.Ivanovic,
and
L.Dosen-Micovic
(2009).
Docking studies suggest ligand-specific delta-opioid receptor conformations.
|
| |
J Mol Model,
15,
267-280.
|
 |
|
|
|
|
 |
A.Gupta,
R.Rozenfeld,
I.Gomes,
K.M.Raehal,
F.M.Décaillot,
L.M.Bohn,
and
L.A.Devi
(2008).
Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies.
|
| |
J Biol Chem,
283,
10735-10744.
|
 |
|
|
|
|
 |
B.R.Myers,
C.J.Bohlen,
and
D.Julius
(2008).
A yeast genetic screen reveals a critical role for the pore helix domain in TRP channel gating.
|
| |
Neuron,
58,
362-373.
|
 |
|
|
|
|
 |
F.M.Décaillot,
R.Rozenfeld,
A.Gupta,
and
L.A.Devi
(2008).
Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4.
|
| |
Proc Natl Acad Sci U S A,
105,
16045-16050.
|
 |
|
|
|
|
 |
S.Sen,
T.J.Baranski,
and
G.V.Nikiforovich
(2008).
Conformational movement of F251 contributes to the molecular mechanism of constitutive activation in the C5a receptor.
|
| |
Chem Biol Drug Des,
71,
197-204.
|
 |
|
|
|
|
 |
T.Yamashita,
A.Terakita,
T.Kai,
and
Y.Shichida
(2008).
Conformational change of the transmembrane helices II and IV of metabotropic glutamate receptor involved in G protein activation.
|
| |
J Neurochem,
106,
850-859.
|
 |
|
|
|
|
 |
A.Gupta,
F.M.Décaillot,
I.Gomes,
O.Tkalych,
A.S.Heimann,
E.S.Ferro,
and
L.A.Devi
(2007).
Conformation state-sensitive antibodies to G-protein-coupled receptors.
|
| |
J Biol Chem,
282,
5116-5124.
|
 |
|
|
|
|
 |
J.Lötsch,
and
G.Geisslinger
(2007).
Current evidence for a modulation of nociception by human genetic polymorphisms.
|
| |
Pain,
132,
18-22.
|
 |
|
|
|
|
 |
M.Scarselli,
B.Li,
S.K.Kim,
and
J.Wess
(2007).
Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation.
|
| |
J Biol Chem,
282,
7385-7396.
|
 |
|
|
|
|
 |
S.Basu,
V.R.Jala,
S.Mathis,
S.T.Rajagopal,
A.Del Prete,
P.Maturu,
J.O.Trent,
and
B.Haribabu
(2007).
Critical role for polar residues in coupling leukotriene B4 binding to signal transduction in BLT1.
|
| |
J Biol Chem,
282,
10005-10017.
|
 |
|
|
|
|
 |
A.Taly,
P.J.Corringer,
T.Grutter,
L.Prado de Carvalho,
M.Karplus,
and
J.P.Changeux
(2006).
Implications of the quaternary twist allosteric model for the physiology and pathology of nicotinic acetylcholine receptors.
|
| |
Proc Natl Acad Sci U S A,
103,
16965-16970.
|
 |
|
|
|
|
 |
F.Merg,
D.Filliol,
I.Usynin,
I.Bazov,
N.Bark,
Y.L.Hurd,
T.Yakovleva,
B.L.Kieffer,
and
G.Bakalkin
(2006).
Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor.
|
| |
J Neurochem,
97,
292-301.
|
 |
|
|
|
|
 |
G.Scherrer,
P.Tryoen-Tóth,
D.Filliol,
A.Matifas,
D.Laustriat,
Y.Q.Cao,
A.I.Basbaum,
A.Dierich,
J.L.Vonesh,
C.Gavériaux-Ruff,
and
B.L.Kieffer
(2006).
Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo.
|
| |
Proc Natl Acad Sci U S A,
103,
9691-9696.
|
 |
|
|
|
|
 |
W.B.Floriano,
S.Hall,
N.Vaidehi,
U.Kim,
D.Drayna,
and
W.A.Goddard
(2006).
Modeling the human PTC bitter-taste receptor interactions with bitter tastants.
|
| |
J Mol Model,
12,
931-941.
|
 |
|
|
|
|
 |
X.Zhang,
L.Bao,
and
J.S.Guan
(2006).
Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance.
|
| |
Trends Pharmacol Sci,
27,
324-329.
|
 |
|
|
|
|
 |
Y.Zhang,
M.E.Devries,
and
J.Skolnick
(2006).
Structure modeling of all identified G protein-coupled receptors in the human genome.
|
| |
PLoS Comput Biol,
2,
e13.
|
 |
|
|
|
|
 |
D.Massotte,
and
B.L.Kieffer
(2005).
The second extracellular loop: a damper for G protein-coupled receptors?
|
| |
Nat Struct Mol Biol,
12,
287-288.
|
 |
|
|
|
|
 |
G.Ladds,
K.Davis,
A.Das,
and
J.Davey
(2005).
A constitutively active GPCR retains its G protein specificity and the ability to form dimers.
|
| |
Mol Microbiol,
55,
482-497.
|
 |
|
|
|
|
 |
H.Weinstein
(2005).
Hallucinogen actions on 5-HT receptors reveal distinct mechanisms of activation and signaling by G protein-coupled receptors.
|
| |
AAPS J,
7,
E871-E884.
|
 |
|
|
|
|
 |
I.D.Pogozheva,
M.J.Przydzial,
and
H.I.Mosberg
(2005).
Homology modeling of opioid receptor-ligand complexes using experimental constraints.
|
| |
AAPS J,
7,
E434-E448.
|
 |
|
|
|
|
 |
J.M.Klco,
C.B.Wiegand,
K.Narzinski,
and
T.J.Baranski
(2005).
Essential role for the second extracellular loop in C5a receptor activation.
|
| |
Nat Struct Mol Biol,
12,
320-326.
|
 |
|
|
|
|
 |
J.S.Guan,
Z.Z.Xu,
H.Gao,
S.Q.He,
G.Q.Ma,
T.Sun,
L.H.Wang,
Z.N.Zhang,
I.Lena,
I.Kitchen,
R.Elde,
A.Zimmer,
C.He,
G.Pei,
L.Bao,
and
X.Zhang
(2005).
Interaction with vesicle luminal protachykinin regulates surface expression of delta-opioid receptors and opioid analgesia.
|
| |
Cell,
122,
619-631.
|
 |
|
|
|
|
 |
R.P.Bywater
(2005).
Location and nature of the residues important for ligand recognition in G-protein coupled receptors.
|
| |
J Mol Recognit,
18,
60-72.
|
 |
|
|
|
|
 |
W.Xu,
M.Campillo,
L.Pardo,
J.Kim de Riel,
and
L.Y.Liu-Chen
(2005).
The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions.
|
| |
Biochemistry,
44,
16014-16025.
|
 |
|
|
|
|
 |
M.Aburi,
and
P.E.Smith
(2004).
Modeling and simulation of the human delta opioid receptor.
|
| |
Protein Sci,
13,
1997-2008.
|
 |
|
|
|
|
 |
M.Daoudi,
E.Lavergne,
A.Garin,
N.Tarantino,
P.Debré,
F.Pincet,
C.Combadière,
and
P.Deterre
(2004).
Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1.
|
| |
J Biol Chem,
279,
19649-19657.
|
 |
|
|
|
|
 |
M.Waldhoer,
S.E.Bartlett,
and
J.L.Whistler
(2004).
Opioid receptors.
|
| |
Annu Rev Biochem,
73,
953-990.
|
 |
|
|
|
|
 |
K.Brillet,
B.L.Kieffer,
and
D.Massotte
(2003).
Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening.
|
| |
BMC Pharmacol,
3,
14.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |